Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Miproxifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.61 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.61 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.61 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.61 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.61 |
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.61 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.61 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.61 |
| ▸ | ESR1 | P03372 | 12/20 | 0.69 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.69 |
| ▸ | ESRRB | O95718 | 4/20 | 0.69 |
| ▸ | ESRRG | P62508 | 4/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | TP53 | P04637 | 2/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.69 |
| ▸ | PGR | P06401 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Miproxifene SCHEMBL3781215 | 1.00 | ESR1 (0.69) | ESR1ESR2ESRRBESRRGMAPT | |
| Miproxifene SCHEMBL3781209 | 1.00 | ESR1 (0.69) | ESR1ESR2ESRRBESRRGMAPT | |
| Miproxifene SCHEMBL409027 | 0.94 | ESR1 (0.76) | ESR1ESR2ESRRBESRRGMAPT | |
| Miproxifene SCHEMBL34173 | 0.94 | ESR1 (0.76) | ESR1ESR2ESRRBESRRGMAPT | |
| Miproxifene SCHEMBL409028 | 0.94 | ESR1 (0.76) | ESR1ESR2ESRRBESRRGMAPT | |
| Miproxifene SCHEMBL9857612 | 0.93 | ESR1 (0.74) | ESR1ESR2ESRRBESRRGMAPT | |
| Miproxifene SCHEMBL9857619 | 0.93 | ESR1 (0.74) | ESR1ESR2ESRRBESRRGMAPT | |
| Miproxifene SCHEMBL9857626 | 0.93 | ESR1 (0.74) | ESR1ESR2ESRRBESRRGMAPT | |
| Miproxifene SCHEMBL2128564 | 0.93 | ESR1 (0.74) | ESR1ESR2ESRRBESRRGMAPT | |
| SCHEMBL2087896 | 0.89 | ESR1 (0.61) | ESR1ESR2ESRRBESRRGMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 340 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106456662-A | Compositions of pentosan polysulfate for oral administration and methods of use thereof | 奥利金制药公司 | 2017-02-22 | — | — | CN | claimed |
| JP-2011528275-A | — | — | 2011-11-17 | — | — | JP | claimed |
| EP-2313122-A1 | DRUG DELIVERY MEDICAL DEVICE | Micell Technologies, Inc. (US) | 2011-04-27 | — | — | EP | claimed |
| WO-2010009335-A1 | DRUG DELIVERY MEDICAL DEVICE | MICELL TECHNOLOGIES, INC. (US) | 2010-01-21 | — | — | WO | claimed |
| WO-2009108361-A1 | METHODS FOR TREATMENT AND PREVENTION OF BREAST CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-09-03 | — | — | WO | claimed |
| CN-100448487-C | Method of treating estrogen receptor positive carcinoma | WYETH CORP (US) | 2009-01-07 | — | — | CN | claimed |
| EP-1135193-B1 | AGENTS PROVIDED FOR TREATING TUMORS, BASED ON LIPOSOMES, AND CONTAINING TAMOXIFEN | MAX DELBRUECK CENTRUM (DE) | 2002-10-30 | — | — | EP | claimed |
| US-20250295634-A1 | USE OF ANTIANDROGENS TO TREAT SEPSIS | RHODE ISLAND HOSPITAL | 2025-09-25 | — | — | US | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-12011432-B2 | Method of modulating ribonucleotide reductase | CASE WESTERN RESERVE UNIVERSITY (US) | 2024-06-18 | — | — | US | disclosed |
| US-11998642-B2 | Multisomes: encapsulated droplet networks | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-06-04 | — | — | US | disclosed |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | EDISON ONCOLOGY (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4297746-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED COMPOUNDS AND THERAPIES FOR THE TREATMENT OF DISEASES | Edison Oncology (US) | 2024-01-03 | — | — | EP | disclosed |
| WO-2000038730-A2 | USE OF A CYCLOOXYGENASE-2 INHIBITOR AND ONE OR MORE ANTINEOPLASTIC AGENTS FOR COMBINATION THERAPY IN NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000038719-A1 | USE OF A MATRIX METALLOPROTEINASE INHIBITOR AND AN INTEGRIN ANTAGONIST IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000038665-A2 | USE OF AN INTEGRIN ANTAGONIST AND ONE OR MORE ANTINEOPLASTIC AGENTS AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000038786-A2 | USE OF CYCLOOXYGENASE 2 INHIBITOR AND AN INTEGRIN ANTAGONIST AS A COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000038718-A2 | USE OF MATRIX METALLOPROTEINASE INHIBITOR TOGETHER WITH AN ANTINEOPLASTIC AGENTS, OPTIONALLY ALSO TOGETHER WITH RADIATION, IN THE TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000037107-A2 | USE OF CYCLOOXYGENASE-2 INHIBITOR, A MATRIX METALLAPROTEINASE INHIBITOR, AN ANTINEOPLASTIC AGENT AND OPTIONALLY RADIATION AS A COMBINATION TREATMENT OF NEOPLASIA | G.D. SEARLE & CO. (US) | 2000-06-29 | — | — | WO | disclosed |
| WO-1999024401-A1 | USE OF ALKYLATED IMINOSUGARS TO TREAT MULTIDRUG RESISTANCE | G.D. SEARLE & CO. (US) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | TOP2A, TOP2B, TOP1 | ADRB2 4296/4885ADRB1 4122/4885ADRB3 3697/4885 |
| US-20250295634-A1 | USE OF ANTIANDROGENS TO TREAT SEPSIS | SHBG, AR, HSD17B11 | ADRB2 611/4885ADRB1 417/4885ADRB3 488/4885 |
| US-12011432-B2 | Method of modulating ribonucleotide reductase | RRM2, RRM2B, RRM1 | ADRB2 2865/4885ADRB1 2260/4885ADRB3 3601/4885 |
| US-11998642-B2 | Multisomes: encapsulated droplet networks | TIMM50, TIMM44, CHMP4B | ADRB2 2423/4885ADRB1 2115/4885ADRB3 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.